| Target | LXR[1] |
|---|
| In Vivo |
Oral administration of GW3965 or RGX-104 to animals bearing
palpable tumors significantly suppresses the growth of multiple cancer
types. Strong tumor growth suppression is also observed in animals
bearing large tumors. In some instances, the treatment causes partial or
complete tumor regression. Responses are seen across a wide spectrum of
malignancies, including lung cancer, melanoma, glioblastoma, and
ovarian, renal cell, triple-negative breast, and colon cancer[1].
|
|---|
| Cell Assay |
Bone marrow cells are cultured with B16F10 melanoma cells and
GM-CSF for 6 days. On day 3, RGX-104 (2 μM) is added to the culture. The
mean number of Gr-1high CD11b+ cells per 50 mL of culture solution is
assessed by flow cytometry on day 6[1].
|
|---|
| Animal Protocol |
Mice[1] B16F10 cancer cells are subcutaneously injected into
C57BL/6 mice. Following tumor growth to 5-10 mm3 in volume, mice are fed
either control chow, chow supplemented with GW3965 (100 mg/kg), or chow
supplemented with RGX-104 (100 mg/kg)[1].
|
|---|
| References | [1]. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Feb 8;172(4):825-840.e18 |
|---|
m.cnreagent.com